BERLIN— The World Health Organization says millions of young people around the world are at risk of hearing loss from loud music. The U.N. agency said Friday that a review of data from middle- and high-income countries shows almost half of all 12 to 35- year-olds listen to unsafe levels of music on their personal audio devices or cellphones. The Geneva- based agency...» Read More
Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.
As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)
Shares of Genentech are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche. Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.
A photographer for the "New York Post" snapped this picture last night of a nattily dressed Sam Waksal returning to a halfway house in the Bronx after going on a little shopping trip.
It was my turn to man the CNBC Alerts Desk earlier today from 9am ET to 1 pm ET. I had finished blogging about the "Barron's bounce" Amylin Pharmaceuticals was getting, based on the speculative mention about it being a potential takeout target for Eli Lilly. Then, I look up at the screen and see AMLN is absolutely tanking...
Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.
The Elanians have been pretty quiet in the wake of last week's bad news. and the stock getting about a two-thirds haircut. And I don't mean to rub salt in the wound.
A week after Bristol-Myers Squibb made its move for ImClone Systems, one of the people who made the biotech infamous could be getting out of the clink.
We reporters who cover biopharma are inundated with story pitches from companies and PR folks. Most of them go immediately into the electronic trash bin. But I couldn't let this one go so fast
Just before the opening bell this morning ImClone Systems put out a clearly Carl Icahn-inspired press release regarding last week's $60-a-share buyout offer from Bristol-Myers Squibb.
What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.
I'm at the International Conference on Alzheimer's Disease--aka ICAD--in Chicago where we're waiting for the highly anticipated detailed test results on the promising experimental drug from Wyeth and Elan.
Amgen surprised the market late on a summer Friday by announcing positive test results from the big, crucial study of its experimental osteoporosis drug. The stock shot up after hours and continues to rally this morning.
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.
So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs. I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.
On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."
Yesterday while covering the press conference about the new study on Merck and Schering-Plough's Vytorin I quoted the lead researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway, who said--and this is a direct quote: "However, we had a disturbing finding when we looked at safety."
The buyout offer from Swiss drug giant Roche has shares of DNA trading at their highest level in about two-and-a-half years and according to CNBC stock-stat maven, Robert Hum, if they close up at least 8.88% it'll be their biggest one-day percentage gain since April 15, 2005.